Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols

NCT00035373

Glioblatoma Gliosarcoma Anaplastic Astrocytoma +2 more

TERMINATED

A Study of ONC201 for Refractory Meningioma

NCT06012929

Meningioma Refractory Meningioma Relapsed Meningioma

WITHDRAWN PHASE2

A Study for Cerebral Open Flow Microperfusion

NCT07089758

Glioma Glioblastoma

NOT_YET_RECRUITING NA

Nimotuzumab in Children With Intrinsic Pontine Glioma

NCT00561691

Diffuse Instrinsic Ponitine Glioma

COMPLETED

Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients

NCT05964153

Glioma Circulating Tumor Cell

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glioma

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ONC201

ONC201 is an oral, small molecule selective antagonist of DRD2

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient with DIPG who failed at least one line of prior therapy such as focal radiation therapy
2. Patient must be \> than 6 months and \< 18 years of age.
3. Confirmed evidence of disease progression from immediately prior therapy or refractory to the immediately prior treatment.
4. Karnofsky/Lansky performance status ≥ 50.
5. Adequate organ and marrow function as defined below:

1. Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment (cycle 1 day 1, C1D1)

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ CONFIDENTIAL Page 3 of 45
2. Hemoglobin\>8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to C1D1
3. Total serum bilirubin\<1.5 X upper limit of normal (ULN)
4. AST (SGOT)/ALT (SGPT)≤2 X ULN;; ≤ 5 X ULN if there is liver involvement secondary to tumor
5. Serum creatinine≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)
6. Ability to understand and the willingness to sign a written informed consent document by the patient or their legal guardian.
7. If patient is of child--bearing age, female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
8. Patient must be able to swallow capsules and retain orally administered medication.

Exclusion Criteria

1. Body weight \>10Kg.
2. Known active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
3. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)--related illness.
4. Active or prior plasma cell leukemia (defined as either 20% of peripheral WBC comprised of plasma/CD138+ cells or an absolute count of 2 x 10\^9/L).
5. Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.
6. Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
7. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.

Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Years

Eligible Sex

Accepts Healthy Volunteers

No